It’s always said that the eyes are a window to the soul, but science now suggests they might also be a window to the heart.

Fintel reports that on July 17, 2025, Needham downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from Buy to Hold. Analyst Price Forecast Suggests 571.05% Upside As of July 16, 2025, ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

SEVILLE, Spain — Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.

Fintel reports that on July 18, 2025, Chardan Capital downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from Buy to Neutral. Analyst Price Forecast Suggests 832.20% Upside As of July ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that ...

Dr. Joseph Ricotta is the national medical director for Vascular Surgery and Endovascular Therapy for Tenet Healthcare and ...